The Role of Copeptin in Heart Failure of Children | ||||
| Zagazig University Medical Journal | ||||
| Article 16, Volume 31, Issue 2, February 2025, Page 724-728 PDF (764.6 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/zumj.2024.333326.3675 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Soad Abd El Salam Shedeed1; Naglaa Ali Khalifa2; Enas Salah Hamza Badawy  3; Marwa L. M. Rashad4
| ||||
| 1Professor of Pediatrics Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| 2Professor of Clinical Pathology, Faculty of Medicine – Zagazig University, Zagazig, Egypt | ||||
| 3Pediatrics Department, Faculty of Medicine, Zagazig University, Egypt | ||||
| 4Lecturer of Pediatrics Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| Abstract | ||||
| Background: In the contemporary Western world, heart failure (HF) is one of the leading causes of hospitalization and death, and its prevalence is expected to rise in the coming years. Despite the fact that HF therapy has improved prognosis and quality of life, death is still relatively high. Neurohormonal inhibition of an overactive neurohormonal axis is the medical therapy approach. In terms of hospitalization, mortality, and the course of the disease, no one sign has been able to predict or track HF. It is necessary to develop new techniques for prognosis, therapeutic monitoring, and diagnosis. A novel biomarker in HF with encouraging promise is copeptin, a precursor of pre-provasopressin. Copeptin is linked to prognosis and has been reported to be increased in both acute and chronic heart failure. Conclusion: Copeptin may be a helpful biomarker for tracking the severity of the disease and for predicting survival and prognosis in HF when combined with other biomarkers. | ||||
| Keywords | ||||
| Copeptin; Heart Failure; Children | ||||
|
Statistics Article View: 34,783 PDF Download: 65 |
||||
